Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.

Abstract

The latest research highlights the role of chemokine signaling pathways in the development of nerve injury-induced pain. Recent studies have provided evidence for the involvement of CCR2 and CCR5 in the pathomechanism underlying neuropathy. Thus, the aim of our study was to compare the effects of a selective CCR2 antagonist (RS504393), selective CCR5 antagonist (maraviroc) and dual CCR2/CCR5 antagonist (cenicriviroc) and determine whether the simultaneous blockade of both receptors is better than blocking only one of them selectively. All experiments were performed using Wistar rats/Swiss albino mice subjected to chronic constriction injury (CCI) of the sciatic nerve. To assess pain-related reactions, the von Frey and cold plate tests were used. The mRNA analysis was performed using RT-qPCR. We demonstrated that repeated intrathecal administration of the examined antagonists attenuated neuropathic pain in rats 7 days post-CCI. mRNA analysis showed that RS504393 did not modulate the spinal expression of the examined chemokines, whereas maraviroc reduced the CCI-induced elevation of CCL4 level. Cenicriviroc significantly lowered the spinal levels of CCL2-4 and CCL7. At the dorsal root ganglia, strong impacts of RS504393 and cenicriviroc on chemokine expression were observed; both reduced the CCI-induced elevation of CCL2-5 and CCL7 levels, whereas maraviroc decreased only the CCL5 level. Importantly, we demonstrated that a single intrathecal/intraperitoneal injection of cenicriviroc had greater analgesic properties than RS504393 or maraviroc in neuropathic mice. Additionally, we demonstrated that cenicriviroc enhanced opioid-induced analgesia. Based on our results, we suggest that targeting CCR2 and CCR5 simultaneously, is an interesting alternative for neuropathic pain pharmacotherapy.

• Authors: Klaudia Kwiatkowski, Katarzyna Ciapała, Ewelina Rojewska, Wioletta Makuch, Joanna Mika
• Journal: International immunopharmacology (Int Immunopharmacol) Vol. 84 Pg. 106540 (Jul 2020) ISSN: 1878-1705 [Electronic] Netherlands
• PMID: 32402949 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright © 2020. Published by Elsevier B.V.

Chemical References

• Analgesics
• Benzoxazines
• CCR5 Receptor Antagonists
• Chemokines, CC
• Imidazoles
• RS 504393
• Receptors, CCR2
• Spiro Compounds
• Sulfoxides
• cenicriviroc
• Maraviroc

Topics

• Analgesics (therapeutic use)
• Animals
• Behavior, Animal (drug effects)
• Benzoxazines (therapeutic use)
• CCR5 Receptor Antagonists (therapeutic use)
• Chemokines, CC (genetics)
• Imidazoles (therapeutic use)
• Injections, Intraperitoneal
• Injections, Spinal
• Male
• Maraviroc (therapeutic use)
• Mice
• Neuralgia (drug therapy, genetics)
• Rats, Wistar
• Receptors, CCR2 (antagonists & inhibitors)
• Sciatic Nerve (injuries)
• Sciatic Neuropathy (drug therapy, genetics)
• Spiro Compounds (therapeutic use)
• Sulfoxides (therapeutic use)